208 related articles for article (PubMed ID: 27099937)
1. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B;
PLoS One; 2016; 11(4):e0142481. PubMed ID: 27099937
[TBL] [Abstract][Full Text] [Related]
2. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).
Kim JW; Lee CK; Lee JK; Jeong SJ; Oh SJ; Moon JR; Kim HS; Kim HJ
Scand J Gastroenterol; 2019 Apr; 54(4):419-426. PubMed ID: 30905222
[No Abstract] [Full Text] [Related]
3. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.
Targownik LE; Benchimol EI; Witt J; Bernstein CN; Singh H; Lix L; Tennakoon A; Zubieta AA; Coward S; Jones J; Kuenzig E; Murthy SK; Nguyen GC; Peña-Sánchez JN; Kaplan G
Inflamm Bowel Dis; 2019 Sep; 25(10):1718-1728. PubMed ID: 31211836
[TBL] [Abstract][Full Text] [Related]
5. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
6. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
8. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
Niewiadomski O; Studd C; Hair C; Wilson J; McNeill J; Knight R; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Tacey M; Connell W; Desmond P; Bell S
J Crohns Colitis; 2015 Nov; 9(11):988-96. PubMed ID: 26129692
[TBL] [Abstract][Full Text] [Related]
9. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
[TBL] [Abstract][Full Text] [Related]
10. Cost of Illness in Inflammatory Bowel Disease.
Kamat N; Ganesh Pai C; Surulivel Rajan M; Kamath A
Dig Dis Sci; 2017 Sep; 62(9):2318-2326. PubMed ID: 28766243
[TBL] [Abstract][Full Text] [Related]
11. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.
Lawton J; Achit H; Pouillon L; Boschetti E; Demore B; Matton T; Tournier C; Prodel M; Peyrin-Biroulet L; Guillemin F
United European Gastroenterol J; 2019 Aug; 7(7):908-913. PubMed ID: 31428415
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
14. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity.
Niewiadomski O; Studd C; Hair C; Wilson J; Ding NS; Heerasing N; Ting A; McNeill J; Knight R; Santamaria J; Prewett E; Dabkowski P; Dowling D; Alexander S; Allen B; Popp B; Connell W; Desmond P; Bell S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1346-53. PubMed ID: 25867770
[TBL] [Abstract][Full Text] [Related]
15. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.
Mandel MD; Balint A; Golovics PA; Vegh Z; Mohas A; Szilagyi B; Szabo A; Kurti Z; Kiss LS; Lovasz BD; Gecse KB; Farkas K; Molnar T; Lakatos PL
Dig Liver Dis; 2014 Nov; 46(11):985-90. PubMed ID: 25156871
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel disease among Bedouin Arabs in southern Israel: urbanization and increasing prevalence rates.
Abu Freha N; Schwartz D; Elkrinawi J; Ben Yakov G; Abu Tailakh M; Munteanu D; Abu Ganim A; Fich A
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):230-4. PubMed ID: 25563139
[TBL] [Abstract][Full Text] [Related]
17. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.
Vester-Andersen MK; Prosberg MV; Jess T; Andersson M; Bengtsson BG; Blixt T; Munkholm P; Bendtsen F; Vind I
Am J Gastroenterol; 2014 May; 109(5):705-14. PubMed ID: 24642581
[TBL] [Abstract][Full Text] [Related]
18. Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort.
Lo B; Vind I; Vester-Andersen MK; Bendtsen F; Burisch J
J Crohns Colitis; 2020 Jan; 14(1):53-63. PubMed ID: 31076743
[TBL] [Abstract][Full Text] [Related]
19. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.
Hiroz P; Vavricka SR; Fournier N; Safroneeva E; Pittet V; Rogler G; Schoepfer AM;
Scand J Gastroenterol; 2014 Oct; 49(10):1207-18. PubMed ID: 25120029
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease.
de Silva PS; Nguyen DD; Sauk J; Korzenik J; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2012 Sep; 36(5):459-66. PubMed ID: 22784296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
